| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 3.75M | 5.35M | 19.39M | 6.77M | 11.98M |
| Revenue Growth % | - | - | 0.43% | 2.62% | -0.65% | 0.77% |
| Cost of Goods Sold | 8.35M | 15.7M | 0 | 0 | 3.48M | 0 |
| COGS % of Revenue | - | 4.19% | - | - | 0.51% | - |
| Gross Profit | -8.35M | -11.95M | 5.35M | 19.39M | 3.29M | 11.98M |
| Gross Margin % | - | -3.19% | 1% | 1% | 0.49% | 1% |
| Gross Profit Growth % | - | -0.43% | 1.45% | 2.62% | -0.83% | 2.65% |
| Operating Expenses | 1.24M | 2.72M | 48.96M | 54.23M | 46.68M | 41.67M |
| OpEx % of Revenue | - | 0.73% | 9.15% | 2.8% | 6.9% | 3.48% |
| Selling, General & Admin | 1.24M | 2.72M | 12.02M | 14.12M | 14.12M | 13.22M |
| SG&A % of Revenue | - | 0.73% | 2.25% | 0.73% | 2.09% | 1.1% |
| Research & Development | 8.35M | 15.7M | 36.95M | 40.1M | 32.56M | 28.45M |
| R&D % of Revenue | - | 4.19% | 6.91% | 2.07% | 4.81% | 2.37% |
| Other Operating Expenses | -8.35M | -15.7M | 0 | 0 | 0 | 0 |
| Operating Income | -9.58M | -14.67M | -43.61M | -34.84M | -43.39M | -29.69M |
| Operating Margin % | - | -3.92% | -8.15% | -1.8% | -6.41% | -2.48% |
| Operating Income Growth % | - | -0.53% | -1.97% | 0.2% | -0.25% | 0.32% |
| EBITDA | -9.48M | -14.46M | -43.05M | -34.06M | -42.78M | -29.23M |
| EBITDA Margin % | - | -3.86% | -8.05% | -1.76% | -6.32% | -2.44% |
| EBITDA Growth % | - | -0.52% | -1.98% | 0.21% | -0.26% | 0.32% |
| D&A (Non-Cash Add-back) | 99K | 213K | 558K | 781K | 612K | 467K |
| EBIT | -9.58M | -14.67M | -41.57M | -31.58M | -41.14M | -23.97M |
| Net Interest Income | -87.3K | -342K | -625K | 257K | 3.2M | 3.24M |
| Interest Income | 0 | 0 | 0 | 339K | 3.67M | 3.76M |
| Interest Expense | 87.3K | 342K | 625K | 82K | 470K | 515K |
| Other Income/Expense | -104K | -1.21M | 1.42M | 3.18M | 1.78M | 5.21M |
| Pretax Income | -9.69M | -15.88M | -42.2M | -31.66M | -41.61M | -24.48M |
| Pretax Margin % | - | -4.24% | -7.89% | -1.63% | -6.15% | -2.04% |
| Income Tax | 0 | 43K | 157K | 249K | 257K | 630K |
| Effective Tax Rate % | 1% | 1% | 1% | 1.01% | 1.01% | 1.03% |
| Net Income | -9.69M | -15.93M | -42.35M | -31.91M | -41.87M | -25.11M |
| Net Margin % | - | -4.25% | -7.92% | -1.65% | -6.19% | -2.1% |
| Net Income Growth % | - | -0.64% | -1.66% | 0.25% | -0.31% | 0.4% |
| Net Income (Continuing) | -9.69M | -15.93M | -42.35M | -31.91M | -41.87M | -25.11M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -21.65 | -39.90 | -2.14 | -1.23 | -1.57 | -0.94 |
| EPS Growth % | - | -0.84% | 0.95% | 0.43% | -0.28% | 0.4% |
| EPS (Basic) | -21.65 | -39.90 | -2.14 | -1.23 | -1.57 | -0.94 |
| Diluted Shares Outstanding | 18.41M | 25.35M | 19.76M | 25.92M | 26.73M | 26.83M |
| Basic Shares Outstanding | 18.41M | 25.35M | 19.76M | 25.92M | 26.73M | 26.83M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 7.62M | 18.22M | 136.5M | 140.53M | 98.9M | 79.3M |
| Cash & Short-Term Investments | 7.34M | 15.82M | 133.2M | 132.87M | 95.57M | 76.58M |
| Cash Only | 7.34M | 15.82M | 90.87M | 100.33M | 44.23M | 35.02M |
| Short-Term Investments | 0 | 0 | 42.33M | 32.53M | 51.34M | 41.56M |
| Accounts Receivable | 69K | 1.14M | 734K | 3.25M | 1.7M | 0 |
| Days Sales Outstanding | - | 111.05 | 50.08 | 61.25 | 91.61 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 151K | 1.15M | 0 | 4.41M | 1.63M | 1.65M |
| Total Non-Current Assets | 1.18M | 2.26M | 2.74M | 2.89M | 2.81M | 1.53M |
| Property, Plant & Equipment | 1.15M | 1.5M | 1.95M | 2.08M | 2.49M | 1.44M |
| Fixed Asset Turnover | - | 2.51x | 2.75x | 9.31x | 2.71x | 8.30x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 30K | 769K | 796K | 809K | 319K | 91K |
| Total Assets | 8.8M | 20.49M | 139.25M | 143.43M | 101.71M | 80.83M |
| Asset Turnover | - | 0.18x | 0.04x | 0.14x | 0.07x | 0.15x |
| Asset Growth % | - | 1.33% | 5.8% | 0.03% | -0.29% | -0.21% |
| Total Current Liabilities | 1.42M | 7.33M | 11.25M | 21.95M | 14.94M | 18.01M |
| Accounts Payable | 422K | 934K | 2.55M | 3.96M | 4.45M | 2.72M |
| Days Payables Outstanding | 18.45 | 21.71 | - | - | 466.05 | - |
| Short-Term Debt | 0 | 0 | 0 | 4.64M | 5.28M | 4.89M |
| Deferred Revenue (Current) | 0 | 0 | 1000K | 0 | 0 | 1000K |
| Other Current Liabilities | 14K | 4.93M | 5.34M | 5.14M | 482K | -26.32M |
| Current Ratio | 5.35x | 2.48x | 12.14x | 6.40x | 6.62x | 4.40x |
| Quick Ratio | 5.35x | 2.48x | 12.14x | 6.40x | 6.62x | 4.40x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.53M | 5.53M | 9.63M | 35.43M | 35.59M | 35.08M |
| Long-Term Debt | 1.27M | 3.6M | 4.28M | 0 | 0 | 0 |
| Capital Lease Obligations | 257K | 271K | 320K | 431K | 591K | 80K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 1.66M | 5.03M | 0 | 0 | 0 |
| Total Liabilities | 2.95M | 12.87M | 20.88M | 57.38M | 50.53M | 53.09M |
| Total Debt | 1.76M | 4.08M | 4.87M | 5.45M | 6.31M | 5.28M |
| Net Debt | -5.57M | -11.74M | -86M | -94.88M | -37.92M | -29.73M |
| Debt / Equity | 0.30x | 0.54x | 0.04x | 0.06x | 0.12x | 0.19x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -109.77x | -42.90x | -69.78x | -424.85x | -92.33x | -57.66x |
| Total Equity | 5.84M | 7.62M | 118.37M | 86.04M | 51.18M | 27.75M |
| Equity Growth % | - | 0.3% | 14.53% | -0.27% | -0.41% | -0.46% |
| Book Value per Share | 0.32 | 0.30 | 5.99 | 3.32 | 1.91 | 1.03 |
| Total Shareholders' Equity | 5.84M | 7.62M | 118.37M | 86.04M | 51.18M | 27.75M |
| Common Stock | 0 | 0 | 3.65M | 3.71M | 3.71M | 3.72M |
| Retained Earnings | -13.7M | -33.39M | -76.16M | -108.07M | -148.07M | -174.97M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -13K | -81K | -6.22M | -12.97M | -10.9M | -12.65M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -8.62M | -9.31M | -28.65M | 4.04M | -40.28M | -19.54M |
| Operating CF Margin % | - | -2.48% | -5.35% | 0.21% | -5.95% | -1.63% |
| Operating CF Growth % | - | -0.08% | -2.08% | 1.14% | -10.96% | 0.51% |
| Net Income | -9.69M | -15.88M | -42.35M | -31.91M | -41.87M | -25.11M |
| Depreciation & Amortization | 259K | 464K | 558K | 781K | 612K | 467K |
| Stock-Based Compensation | 192K | 557K | 0 | 0 | 5.04M | 3.23M |
| Deferred Taxes | 0 | -43K | 0 | 0 | 0 | -10K |
| Other Non-Cash Items | 0 | 869K | 2.31M | 1.06M | -187K | -2.5M |
| Working Capital Changes | 621K | 4.73M | 10.84M | 34.11M | -3.88M | 4.38M |
| Change in Receivables | 81K | -1.26M | 742K | -2.48M | 1.59M | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -190K | 323K | 1.62M | 1.41M | 352K | -1.57M |
| Cash from Investing | -792K | -502K | -43.55M | 9.35M | -17.64M | 12.47M |
| Capital Expenditures | -762K | -502K | -764K | -587K | -731K | -23K |
| CapEx % of Revenue | - | 0.13% | 0.14% | 0.03% | 0.11% | 0% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.18M | 18.97M | 151.16M | 283K | 0 | -569K |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 0 | 0 | -340K | -343K | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -9.38M | -9.81M | -29.41M | 3.46M | -41.01M | -19.57M |
| FCF Margin % | - | -2.62% | -5.5% | 0.18% | -6.06% | -1.63% |
| FCF Growth % | - | -0.05% | -2% | 1.12% | -12.87% | 0.52% |
| FCF per Share | -0.51 | -0.39 | -1.49 | 0.13 | -1.53 | -0.73 |
| FCF Conversion (FCF/Net Income) | 0.89x | 0.58x | 0.68x | -0.13x | 0.96x | 0.78x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 355K | 283K |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -165.76% | -236.57% | -67.24% | -31.22% | -61.03% | -63.64% |
| Return on Invested Capital (ROIC) | - | - | -231.59% | -222.18% | -1473.65% | -395.17% |
| Gross Margin | - | -319.03% | 100% | 100% | 48.56% | 100% |
| Net Margin | - | -425.06% | -791.68% | -164.55% | -618.57% | -209.6% |
| Debt / Equity | 0.30x | 0.54x | 0.04x | 0.06x | 0.12x | 0.19x |
| Interest Coverage | -109.77x | -42.90x | -69.78x | -424.85x | -92.33x | -57.66x |
| FCF Conversion | 0.89x | 0.58x | 0.68x | -0.13x | 0.96x | 0.78x |
| Revenue Growth | - | - | 42.78% | 262.45% | -65.09% | 77.01% |
| 2024 | |
|---|---|
| Netherlands | 11.98M |
| Netherlands Growth | - |
LAVA Therapeutics N.V. (LVTX) reported $5.0M in revenue for fiscal year 2024.
LAVA Therapeutics N.V. (LVTX) grew revenue by 77.0% over the past year. This is strong growth.
LAVA Therapeutics N.V. (LVTX) reported a net loss of $23.3M for fiscal year 2024.
LAVA Therapeutics N.V. (LVTX) has a return on equity (ROE) of -63.6%. Negative ROE indicates the company is unprofitable.
LAVA Therapeutics N.V. (LVTX) had negative free cash flow of $31.7M in fiscal year 2024, likely due to heavy capital investments.